Keyphrases
13-valent
32%
13-valent Pneumococcal Conjugate Vaccine (PCV13)
32%
5-year-old
9%
7-valent
32%
Antiretroviral Therapy
16%
Bacteremia
8%
Carbapenem-resistant Bacteria
16%
Carbapenem-resistant Enterobacteria
8%
Ceftazidime-avibactam
16%
Cetuximab
16%
Chemotherapy
16%
Chemotherapy Alone
16%
Chronic Hepatitis B
16%
Colistin
10%
Cost-effectiveness
87%
Cost-effectiveness Analysis
32%
Economic Model
7%
Entecavir
16%
GDP per Capita
16%
Health Care Costs
12%
Health Status
6%
High Cost
12%
Hospitalization
14%
Incremental Cost-effectiveness Ratio
13%
Interferon Therapy
32%
Interferon-α (IFN-α)
28%
Ischemic Heart Disease
16%
Markov Model
7%
Metastatic Colorectal Cancer (mCRC)
16%
Ministry of Health
7%
Multiple Sclerosis
32%
Patient Support
32%
Patterns of Care
16%
PCV10
28%
PCV7
28%
Peru
100%
Peruvian
39%
Pneumococcal Conjugate Vaccine
32%
Pneumonia
41%
Public Hospitals
6%
Quality-adjusted Life Years
14%
Sensitivity Analysis
7%
Streptococcus Pneumoniae
9%
Tenofovir
16%
Tornado Analysis
5%
Treatment Adherence
32%
Treatment Impact
32%
Treatment Strategy
16%
Willingness to Pay
6%
Pharmacology, Toxicology and Pharmaceutical Science
Antiviral Therapy
16%
Avibactam Plus Ceftazidime
16%
Bloodstream Infection
8%
Carbapenem
16%
Cetuximab
16%
Chemotherapy
16%
Chronic Hepatitis B
16%
Colistimethate
10%
Entecavir
16%
Enterobacteriaceae
8%
Health Status
6%
Infection
16%
Interferon
32%
Metastatic Colon Cancer
16%
Multiple Sclerosis
32%
Pneumococcus Vaccine
16%
Streptococcus Pneumonia
10%
Tenofovir
16%
Nursing and Health Professions
Cetuximab
16%
Cost Effectiveness Analysis
49%
Disease
6%
Interferon
32%
Ischemic Heart Disease
16%
Metastatic Colon Cancer
16%
Multiple Sclerosis
32%
Patient Compliance
32%
Quality Adjusted Life Year
11%